Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
4.755
+0.025 (0.53%)
Nov 3, 2026, 11:46 AM EST - Market open
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year. That makes Savara the 33,480th largest employer in the world and 4,414th in the United States.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,990,129
Market Cap
1.21B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| Syndax Pharmaceuticals | 298 |
| Kardigan | 241 |
| Alpha Tau Medical | 121 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Vor Biopharma | 76 |
| Nektar Therapeutics | 63 |
SVRA News
- 12 days ago - Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment - Business Wire
- 21 days ago - Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 - Business Wire
- 26 days ago - Savara Slides: Corporate presentation - Filings
- 27 days ago - Savara initiated with an Overweight at JPMorgan - TheFly
- 2 months ago - Savara announces presentations of Results from Phase 3 trial of Molgramostim - TheFly
- 2 months ago - Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Business Wire
- 2 months ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara reports Q2 EPS (16c), consensus (15c) - TheFly